A common matrix metalloproteinase (MMP)-2 polymorphism affects plasma MMP-2 levels in subjects environmentally exposed to mercury

Science of the Total Environment

Volumn 409, Issue 20, 2011, Pages 4242-4246

  Jacob Ferreira, Anna L B ^a   Lacchini, Riccardo ^a   Gerlach, Raquel F ^b   Passos, Carlos J S ^c   Barbosa Jr , Fernando ^b   Tanus Santos, Jose E ^b  

^a UNIVERSITY OF CAMPINAS   (Brazil)

^b UNIVERSITY OF SÃO PAULO   (Brazil)

^c UNIVERSITY OF BRASILIA   (Brazil)

Author keywords

Matrix metalloproteinases; Mercury; Polymorphism

Indexed keywords

ACTIVITY LEVELS; ENDOGENOUS INHIBITOR; GELATIN ZYMOGRAPHY; GENETIC POLYMORPHISMS; HG CONCENTRATIONS; MATRIX METALLOPROTEINASES; PLASMA SAMPLES; PROMOTER ACTIVITIES; TISSUE INHIBITOR;

ENZYME ACTIVITY; ENZYME INHIBITION; GENE ENCODING; GENE EXPRESSION; INDUCTIVELY COUPLED PLASMA; MASS SPECTROMETRY; MERCURY (METAL); TISSUE;

BLOOD VESSELS;

CYTOSINE; GELATIN; GELATINASE A; MERCURY; THYMINE; TISSUE INHIBITOR OF METALLOPROTEINASE 2;

ALLELE; ENZYME ACTIVITY; INHIBITOR; MERCURY (ELEMENT); POLLUTION EXPOSURE; POLYMORPHISM;

ADOLESCENT; ADULT; AGED; ALLELE; ARTICLE; BLOOD LEVEL; ENVIRONMENTAL EXPOSURE; ENZYME ACTIVITY; ENZYME BLOOD LEVEL; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GELATINASE A BLOOD LEVEL; GENETIC POLYMORPHISM; GENOTYPE; HETEROZYGOTE; HUMAN; MALE; MASS SPECTROMETRY; MERCURY BLOOD LEVEL; PRIORITY JOURNAL; TISSUE INHIBITOR OF METALLOPROTEINASE 2 BLOOD LEVEL; ZYMOGRAPHY;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; BRAZIL; CARDIOVASCULAR DISEASES; ENVIRONMENTAL EXPOSURE; ENVIRONMENTAL POLLUTANTS; FEMALE; GENOTYPE; HUMANS; MALE; MATRIX METALLOPROTEINASE 2; MERCURY; MIDDLE AGED; POLYMORPHISM, GENETIC; QUESTIONNAIRES; RISK; TISSUE INHIBITOR OF METALLOPROTEINASE-2; YOUNG ADULT;

EID: 80052047940     PISSN: 00489697     EISSN: 18791026     Source Type: Journal    
DOI: 10.1016/j.scitotenv.2011.07.013     Document Type: Article

References (46)

1. Belo V.A., Souza-Costa D.C., Lana C.M., Caputo F.L., Marcaccini A.M., Gerlach R.F., et al. Assessment of matrix metalloproteinase (MMP)-2, MMP-8, MMP-9, and their inhibitors, the tissue inhibitors of metalloproteinase (TIMP)-1 and TIMP-2 in obese children and adolescents. Clin Biochem 2009, 42:984-990.
2. Belvisi M.G., Bottomley K.M. The role of matrix metalloproteinases (MMPs) in the pathophysiology of chronic obstructive pulmonary disease (COPD): a therapeutic role for inhibitors of MMPs?. Inflamm Res 2003, 52:95-100.
3. Berglund M., Lind B., Bjornberg K.A., Palm B., Einarsson O., Vahter M. Inter-individual variations of human mercury exposure biomarkers: a cross-sectional assessment. Environ Health 2005, 4:20.
4. Boffetta P., Sallsten G., Garcia-Gomez M., Pompe-Kirn V., Zaridze D., Bulbulyan M., et al. Mortality from cardiovascular diseases and exposure to inorganic mercury. Occup Environ Med 2001, 58:461-466.
5. Bonnema D.D., Webb C.S., Pennington W.R., Stroud R.E., Leonardi A.E., Clark L.L., et al. Effects of age on plasma matrix metalloproteinases (MMPs) and tissue inhibitor of metalloproteinases (TIMPs). J Card Fail 2007, 13:530-540.
6. Castro M.M., Rizzi E., Figueiredo-Lopes L., Fernandes K., Bendhack L.M., Pitol D.L., et al. Metalloproteinase inhibition ameliorates hypertension and prevents vascular dysfunction and remodeling in renovascular hypertensive rats. Atherosclerosis 2008, 198:320-331.
7. Castro M.M., Rizzi E., Rodrigues G.J., Ceron C.S., Bendhack L.M., Gerlach R.F., et al. Antioxidant treatment reduces matrix metalloproteinase-2-induced vascular changes in renovascular hypertension. Free Radic Biol Med 2009, 46:1298-1307.
8. Castro M.M., Rizzi E., Prado C.M., Rossi M.A., Tanus-Santos J.E., Gerlach R.F. Imbalance between matrix metalloproteinases and tissue inhibitor of metalloproteinases in hypertensive vascular remodeling. Matrix Biol 2010, 29:194-201.
9. Ceron C.S., Castro M.M., Rizzi E., Montenegro M.F., Fontana V., Salgado M.C., et al. Spironolactone and hydrochlorothiazide exert antioxidant effects and reduce vascular matrix metalloproteinase-2 activity and expression in a model of renovascular hypertension. Br J Pharmacol 2010, 160:77-87.
10. Chow A.K., Cena J., Schulz R. Acute actions and novel targets of matrix metalloproteinases in the heart and vasculature. Br J Pharmacol 2007, 152:189-205.
11. Clarkson T.W., Magos L. The toxicology of mercury and its chemical compounds. Crit Rev Toxicol 2006, 36:609-662.
12. de Marco K.C., Passos C.J., Sertorio J., Tanus-Santos J.E., Barbosa F. Environmental Exposure to Methylmercury is Associated with a Decrease in Nitric Oxide Production. Basic Clin Pharmacol Toxicol 2010, 106:411-415.
13. Demacq C., Vasconcellos V.B., Marcaccini A.M., Gerlach R.F., Machado A.A., Tanus-Santos J.E. A genetic polymorphism of matrix metalloproteinase 9 (MMP-9) affects the changes in circulating MMP-9 levels induced by highly active antiretroviral therapy in HIV patients. Pharmacogenomics J 2009, 9:265-273.
14. Gerlach R.F., Demacq C., Jung K., Tanus-Santos J.E. Rapid separation of serum does not avoid artificially higher matrix metalloproteinase (MMP)-9 levels in serum versus plasma. Clin Biochem 2007, 40:119-123.
15. Gillian L., Fassett J.D., Gerson B., Nixon D.E., Parsons P.J., Savory J. Control of preanalytical variation in trace element determinations; approved guideline. National Committee for Clinical Laboratory Standards 1997, 17:C-38A.
16. Goncalves F.M., Jacob-Ferreira A.L., Gomes V.A., Casella-Filho A., Chagas A.C., Marcaccini A.M., et al. Increased circulating levels of matrix metalloproteinase (MMP)-8, MMP-9, and pro-inflammatory markers in patients with metabolic syndrome. Clin Chim Acta 2009, 403:173-177.
17. Goulle J.P., Mahieu L., Castermant J., Neveu N., Bonneau L., Laine G., et al. Metal and metalloid multi-elementary ICP-MS validation in whole blood, plasma, urine and hair. Reference values. Forensic Sci Int 2005, 153:39-44.
18. Guallar E., Sanz-Gallardo M.I., van't Veer P., Bode P., Aro A., Gomez-Aracena J., et al. Mercury, fish oils, and the risk of myocardial infarction. N Engl J Med 2002, 347:1747-1754.
19. Hojo Y., Ikeda U., Ueno S., Arakawa H., Shimada K. Expression of matrix metalloproteinases in patients with acute myocardial infarction. Jpn Circ J 2001, 65:71-75.
20. Jacob-Ferreira A.L., Passos C.J., Jordao A.A., Fillion M., Mergler D., Lemire M., et al. Mercury exposure increases circulating net matrix metalloproteinase (MMP)-2 and MMP-9 activities. Basic Clin Pharmacol Toxicol 2009, 105:281-288.
21. Jacob-Ferreira A.L., Passos C.J., Gerlach R.F., Barbosa F., Tanus-Santos J.E. A functional matrix metalloproteinase (MMP)-9 polymorphism modifies plasma MMP-9 levels in subjects environmentally exposed to mercury. Sci Total Environ 2010, 408:4085-4092.
22. Kai H., Ikeda H., Yasukawa H., Kai M., Seki Y., Kuwahara F., et al. Peripheral blood levels of matrix metalloproteases-2 and -9 are elevated in patients with acute coronary syndromes. J Am Coll Cardiol 1998, 32:368-372.
23. Lacchini R., Jacob-Ferreira A.L., Luizon M.R., Coeli F.B., Izidoro-Toledo T.C., Gasparini S., et al. Matrix metalloproteinase 9 gene haplotypes affect left ventricular hypertrophy in hypertensive patients. Clin Chim Acta 2010, 411:1940-1944.
24. Martinez M.L., Castro M.M., Rizzi E., Fernandes K., Demacq C., Bendhack L.M., et al. Lercanidipine reduces matrix metalloproteinase-2 activity and reverses vascular dysfunction in renovascular hypertensive rats. Eur J Pharmacol 2008, 591:224-230.
25. Martins-Oliveira A., Speciali J.G., Dach F., Marcaccini A.M., Goncalves F.M., Gerlach R.F., et al. Different circulating metalloproteinases profiles in women with migraine with and without aura. Clin Chim Acta 2009, 408:60-64.
26. Mergler D., Anderson H.A., Chan L.H., Mahaffey K.R., Murray M., Sakamoto M., et al. Methylmercury exposure and health effects in humans: a worldwide concern. Ambio 2007, 36:3-11.
27. Morimoto Y., Tsuda T., Nakamura H., Hori H., Yamato H., Nagata N., et al. Expression of matrix metalloproteinases, tissue inhibitors of metalloproteinases, and extracellular matrix mRNA following exposure to mineral fibers and cigarette smoke in vivo. Environ Health Perspect 1997, 105(Suppl 5):1247-1251.
28. Ning W., Dong Y., Sun J., Li C., Matthay M.A., Feghali-Bostwick C.A., et al. Cigarette smoke stimulates matrix metalloproteinase-2 activity via EGR-1 in human lung fibroblasts. Am J Respir Cell Mol Biol 2007, 36:480-490.
29. Noji Y., Shimizu M., Ino H., Higashikata T., Yamaguchi M., Nohara A., et al. Increased circulating matrix metalloproteinase-2 in patients with hypertrophic cardiomyopathy with systolic dysfunction. Circ J 2004, 68:355-360.
30. Paczek L., Michalska W., Bartlomiejczyk I. Trypsin, elastase, plasmin and MMP-9 activity in the serum during the human ageing process. Age Ageing 2008, 37:318-323.
31. Palei A.C., Sandrim V.C., Cavalli R.C., Tanus-Santos J.E. Comparative assessment of matrix metalloproteinase (MMP)-2 and MMP-9, and their inhibitors, tissue inhibitors of metalloproteinase (TIMP)-1 and TIMP-2 in preeclampsia and gestational hypertension. Clin Biochem 2008, 41:875-880.
32. Palmer C.D., Lewis M.E., Geraghty C.M., Barbosa F., Parsons P.J. Determination of lead, cadmium and mercury in blood for assessment of environmental exposure: a comparison between inductively coupled plasma-mass spectrometry and atomic absorption spectrometry. Spectrochim Acta Part B At Spectrosc 2006, 61:980-990.
33. Passos C.J., Da Silva D.S., Lemire M., Fillion M., Guimaraes J.R., Lucotte M., et al. Daily mercury intake in fish-eating populations in the Brazilian Amazon. J Expo Sci Environ Epidemiol 2008, 18:76-87.
34. Price S.J., Greaves D.R., Watkins H. Identification of novel, functional genetic variants in the human matrix metalloproteinase-2 gene: role of Sp1 in allele-specific transcriptional regulation. J Biol Chem 2001, 276:7549-7558.
35. Ra H.J., Parks W.C. Control of matrix metalloproteinase catalytic activity. Matrix Biol 2007, 26:587-596.
36. Raitio A., Tuomas H., Kokkonen N., Salo T., Sorsa T., Hanemaaijer R., et al. Levels of matrix metalloproteinase-2, -9 and -8 in the skin, serum and saliva of smokers and non-smokers. Arch Dermatol Res 2005, 297:242-248.
37. Rizzi E., Castro M.M., Prado C.M., Silva C.A., Fazan R., Rossi M.A., et al. Matrix metalloproteinase inhibition improves cardiac dysfunction and remodeling in 2-kidney, 1-clip hypertension. J Card Fail 2010, 16:599-608.
38. Salonen J.T., Seppanen K., Lakka T.A., Salonen R., Kaplan G.A. Mercury accumulation and accelerated progression of carotid atherosclerosis: a population-based prospective 4-year follow-up study in men in eastern Finland. Atherosclerosis 2000, 148:265-273.
39. Segura-Valdez L., Pardo A., Gaxiola M., Uhal B.D., Becerril C., Selman M. Upregulation of gelatinases A and B, collagenases 1 and 2, and increased parenchymal cell death in COPD. Chest 2000, 117:684-694.
40. Souza-Costa D.C., Sandrim V.C., Lopes L.F., Gerlach R.F., Rego E.M., Tanus-Santos J.E. Anti-inflammatory effects of atorvastatin: modulation by the T-786C polymorphism in the endothelial nitric oxide synthase gene. Atherosclerosis 2007, 193:438-444.
41. Van den Steen P.E., Dubois B., Nelissen I., Rudd P.M., Dwek R.A., Opdenakker G. Biochemistry and molecular biology of gelatinase B or matrix metalloproteinase-9 (MMP-9). Crit Rev Biochem Mol Biol 2002, 37:375-536.
42. Virtanen J.K., Voutilainen S., Rissanen T.H., Mursu J., Tuomainen T.P., Korhonen M.J., et al. Mercury, fish oils, and risk of acute coronary events and cardiovascular disease, coronary heart disease, and all-cause mortality in men in eastern Finland. Arterioscler Thromb Vasc Biol 2005, 25:228-233.
43. Virtanen J.K., Rissanen T.H., Voutilainen S., Tuomainen T.P. Mercury as a risk factor for cardiovascular diseases. J Nutr Biochem 2007, 18:75-85.
44. Visse R., Nagase H. Matrix metalloproteinases and tissue inhibitors of metalloproteinases: structure, function, and biochemistry. Circ Res 2003, 92:827-839.
45. Woessner J.F. The matrix metalloproteinase family. Matrix metalloproteinases 1998, 1-14. Academic Press, San Diego, CA. W.C. Parks, R.P. Mecham (Eds.).
46. Wright J.L., Tai H., Wang R., Wang X., Churg A. Cigarette smoke upregulates pulmonary vascular matrix metalloproteinases via TNF-alpha signaling. Am J Physiol Lung Cell Mol Physiol 2007, 292:L125-L133.